Vaccine dilemma: To take or not to take Covaxin
True, in the U.S., vaccines from both Pfizer and Moderna are available and recipients, who are health-care workers and nursing home residents, have no option to choose the vaccine. In…
Category: Moderna
I would not take Covaxin without efficacy data: Gagandeep Kang
Scientists, manufacturers and drug regulators have been speeding up the timelines to develop, test and approve vaccines for emergency use. Three safe and efficacious vaccines from Pfizer, Moderna and AstraZeneca…
Why people with prior SARS-CoV-2 infection still need to be vaccinated
Since vaccine shortage is expected to last at least for a few months, it may seem appealing to delay or avoid vaccinating those who have been naturally infected. But does…
UK uses an untested strategy to rapidly but partially protect people at risk
With the virus running amok in the country and vaccines in short-supply, the U.K. is attempting an untested strategy of delaying the second dose of both AstraZeneca and Pfizer vaccine even in the absence of data from large trials. The intent is to rapidly but partially protect more individuals who are at risk.
Can COVID-19 vaccines with EUA be used at the population level?
Meanwhile, the Indian government has spelt out four high-risk groups — healthcare workers, frontline workers, those over 50 years of age and those aged below 50 years but with co-morbidities…
Transparency in COVID-19 vaccine trials vital to gain public trust
Unlike Pfizer, AstraZeneca, which is carrying out the phase-3 trials of the Oxford vaccine in four countries, is yet to secure a nod from any of the regulatory agencies despite…
COVID-19: Challenges in achieving herd immunity through vaccination
But the government’s idea of vaccinating a “critical mass of people” for the purpose of breaking the virus transmission chain is riddled with problems. Unlike the mRNA vaccines from Pfizer…
Moderna’s mRNA vaccine has 94.1% efficacy in final analysis, has applied for EUA
According to the release, the Phase-3 trial has exceeded two months of median follow-up post vaccination as required by the U.S. FDA for the purpose of Emergency Use Authorization (EUA). While the…
Science Chronicle 